Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBIT (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBIT for 7 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 55.78% to -$23.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$156.4 million, a 31.52% increase, with the full-year FY2025 number at -$156.4 million, up 31.52% from a year prior.
  • EBIT was -$23.6 million for Q4 2025 at Pliant Therapeutics, up from -$28.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$22.9 million in Q2 2021 to a low of -$62.0 million in Q3 2024.
  • A 5-year average of -$39.7 million and a median of -$39.7 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 308.2% in 2021, then soared 55.78% in 2025.
  • Pliant Therapeutics' EBIT stood at -$24.6 million in 2021, then tumbled by 52.04% to -$37.4 million in 2022, then fell by 25.77% to -$47.0 million in 2023, then decreased by 13.36% to -$53.3 million in 2024, then skyrocketed by 55.78% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's EBIT are -$23.6 million (Q4 2025), -$28.3 million (Q3 2025), and -$45.6 million (Q2 2025).